Clinical, hemodynamic, and safety outcomes of sotatercept in pulmonary arterial hypertension: a meta-analysis of randomized trials with time-to-event data
Therapeutic Advances in Respiratory Disease · 2026
DOI: 10.1177/17534666261459209 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Therapeutic Advances in Respiratory Disease, 2026. Verfasst von Mohamed R Murad und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research Group of Egypt (MRGE), Negida Academy, Arlington, MA, USA. Hauptthemen laut MEDLINE: Hemodynamics, Pulmonary Arterial Hypertension, Antihypertensive Agents, Recombinant Fusion Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Pulmonary arterial hypertension (PAH) remains progressive despite contemporary background therapy. Sotatercept is a novel activin signaling inhibitor that targets pulmonary vascular remodeling and may improve clinical and hemodynamic outcomes.
Objectives
To evaluate the efficacy, hemodynamic effects, and safety of sotatercept in patients with PAH.
Design
Systematic review and meta-analysis of randomized controlled trials (RCTs). Data sources and methods: Five electronic databases were searched through October 2, 2025, for eligible RCTs. Time-to-event outcomes were analyzed using pooled individual patient data with hazard ratios (HRs), while secondary outcomes were assessed using random-effects risk ratios (RRs) and mean differences (MDs), with 95% confidence intervals (CI). Trial-sequential analysis (TSA) evaluated the conclusiveness of results.
Results
In four RCTs ( n = 889), sotatercept reduced clinical worsening or death by 77% (HR 0.23, 95% CI 0.16–0.32, p < 0.001) and prolonged event-free survival by ~40 weeks. World Health Organization (WHO) functional class improved in 40.3% vs 24.3% (RR 1.71, 95% CI 1.32–2.21), and 6-minute walk distance increased by MD 30.27 m (95% CI 13.45–47.08), while pulmonary vascular resistance (PVR) declined significantly (MD −247 dyn·s·cm– 5 , 95% CI −301.7; −192.2). Serious adverse events were slightly less frequent with sotatercept (26.2% vs 31.7%, RR 0.83); however, total bleeding (37.9% vs 18.7%, RR 2.00), epistaxis (26.7% vs 5.4%, RR 4.89), and telangiectasia (19.8% vs 6.4%, RR 3.24) were more common. TSA revealed conclusiveness in clinical worsening, WHO functional class, and PVR, as well as increases in bleeding events and epistaxis.
Conclusion
Sotatercept significantly improves clinical outcomes and extends event-free survival in PAH, with an acceptable safety profile; however, caution is warranted regarding bleeding events. These results support its role as an add-on therapy in PAH management.
Trial registration
PROSPERO ID: CRD420251166414.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Research Group of Egypt (MRGE), Negida Academy, Arlington, MA, USA.
- Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
- Department of Medicine, An-Najah National University, Rafidia Street, P.O. Box 7, Nablus, West Bank P4110257, Palestine.
- Faculty of Medicine, Tanta University, Tanta, Gharbia, Egypt.
- Department of Medicine, Advocate Illinois Masonic Medical Center, Chicago, IL, USA.
- Department of Pulmonary and Critical Care Medicine, University of Toledo, Toledo, OH, USA.
ORCID-Profile: Mohamed R Murad, Ameer Awashra, Abdalhakim Shubietah
Zitieren
APA
R Murad, M., Awashra, A., S Elgendy, M., Kasem, A. W., Shubietah, A., & Safi, F. (2026). Clinical, hemodynamic, and safety outcomes of sotatercept in pulmonary arterial hypertension: a meta-analysis of randomized trials with time-to-event data. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666261459209
Vancouver
R Murad M, Awashra A, S Elgendy M, Kasem AW, Shubietah A, Safi F. Clinical, hemodynamic, and safety outcomes of sotatercept in pulmonary arterial hypertension: a meta-analysis of randomized trials with time-to-event data. Therapeutic Advances in Respiratory Disease. 2026. doi:10.1177/17534666261459209
BibTeX
@article{RMurad2026,
author = {R Murad, Mohamed and Awashra, Ameer and S Elgendy, Mohamed and Kasem, Ahmed Wahdan and Shubietah, Abdalhakim and Safi, Fadi},
title = {Clinical, hemodynamic, and safety outcomes of sotatercept in pulmonary arterial hypertension: a meta-analysis of randomized trials with time-to-event data},
journal = {Therapeutic Advances in Respiratory Disease},
year = {2026},
doi = {10.1177/17534666261459209}
}
EUVIMED